sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Announce New IL-17 Antagonist Development
Protagonist Therapeutics, based in Newark, California, will hold a conference call and webcast to introduce its new oral peptide IL-17 antagonist development candidate. This announcement will take place on Thursday, November 21st at 4:30 pm ET. The event will also present results from in vitro and pre-clinical proof-of-concept studies.
Protagonist Therapeutics is recognized for its late-stage biopharmaceutical developments. Currently, the company is advancing two novel peptides in Phase 3 clinical trials. The candidate icotrokinra, licensed to Johnson & Johnson, targets IL-23-mediated diseases like psoriasis. Another candidate, rusfertide, is focused on polycythemia vera under collaboration with Takeda Pharmaceuticals.
Additional information about the company's endeavors and drug candidates is available on the Protagonist Therapeutics website.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.